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Summary Hepatocyte growth factor/scatter factor (HGF/SF) stimulates the invasive growth of epithelial cells
via the c-MET oncogene-encoded receptor. In normal lung, both the receptor and the ligand are detected, and
the latter is known to be a mitogenic and a motogenic factor for both cultured bronchial epithelial cells and
non-small-cell carcinoma lines. Here, ligand and receptor expression was examined in 42 samples of primary
human non-small-cell lung carcinoma of different histotype. Each carcinoma sample was compared with
adjacent normal lung tissue. The MetlHGF receptor was found to be 2 to 10-fold increased in 25% of
carcinoma samples (P=0.0113). The ligand, HGF/SF, was found to be 10 to 100-fold overexpressed in
carcinoma samples (P<0.0001). Notably, while HGF/SF was occasionally detectable and found exclusively as
a single-chain inactive precursor in normal tissues, it was constantly in the biologically-active heterodimeric
form in carcinomas. Immunohistochemical staining showed homogeneous expression of both the receptor and
the ligand in carcinoma samples, whereas staining was barely detectable in their normal counterparts. These
data show that HGF/SF is overexpressed and consistently activated in non-small-cell lung carcinomas and may
contribute to the invasive growth of lung cancer.
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Hepatocyte growth factor/scatter factor (HGF/SF) stimulates
a broad spectrum of epithelial cells (in addition to other
selected cell types) to proliferate, move and also carry out
complex differentiation programmes, such as morphogenesis
and angiogenesis (for reviews see Goldberg and Rosen, 1993).
The HGF/SF receptor, encoded by the c-MET oncogene (for
a review, see Comoglio, 1993), is expressed in several normal
human epithelial tissues and is often overexpressed in
carcinomas (Di Renzo et al., 1991, 1992, 1994, 1995a, b;
Prat et al., 1991).
HGF/SF is expressed in rodent and human lung at a low
level (Tashiro et al., 1990; Iyer et al., 1990). However, the
lung becomes a major source of HGF/SF, thus behaving as
an endocrine organ, producing and secreting HGF/SF in
response to distal organ injury (Tashiro et al., 1990; Rubin et
al., 1991). The increased level of circulating HGF/SF
following partial hepatectomy or chemical injury to the liver
correlates to a marked increase of HGF/SF mRNA
expression in the intact lung. HGF/SF increases also in
regenerating lung after chemically induced lung injury in rat
(Yanagita et al., 1992). Experiments in vitro show that HGF/
SF stimulates mitogenesis and/or motogenesis of human
bronchial epithelial cells (Tsao et al., 1993) and alveolar type
II cells (Mason et al., 1994). The factor is produced by non-
epithelial cells of the lung (Stoker et al., 1987; Rubin et al.,
1991) and is considered primarily an endocrine or paracrine
mediator. An autocrine activity on cultured human normal
bronchial epithelial cells has been reported (Tsao et al., 1993).
However, only a small amount of HGF/SF is produced by
either lung fibroblasts or bronchial cells, under the same
conditions. In addition, HGF/SF is secreted as an inactive
precursor (pro-HGF) that binds the extracellular matrix
(Mizuno et al., 1992; Naka et al., 1992; Naldini et al., 1992;
Masumoto et al., 1991). In the extracellular environment,
pro-HGF is converted to the mature heterodimer and
activated either by uPA secreted by the cells themselves
(Naldini et al., 1992) or non-specifically by serum proteases,
such as blood-coagulation factor XIIa and its homologous
protein named HGF-activator (Miyazawa et al., 1993;
Shimomura et al., 1995). In human non-small-cell lung
cancer, (NSCLC) the levels of uPA and uPA inhibitors
(PAI-I and PAI-2) are significantly altered, the former being
higher and the latter lower than in normal tissues (Liu et al.,
1995; Nagayama et al., 1994). PAI-2 decrease is significantly
related to NSCLC spread to lymph nodes (Nagayama et al.,
1994). Bearing this in mind, we postulated that uPA might
promote the invasive properties of NSCLC via HGF/SF
activation. In this paper, we show that HGF/SF is markedly
increased in NSCLC in the form of the processed, i.e.
biologically active, molecule.
Materials and methods
Tissue samples
Primary carcinomas from 42 patients not previously
subjected to chemo- or radiotherapy were analysed. Tissue
samples removed at surgery were dissected by the pathologist.
Normal and neoplastic tissues were immediately frozen in
liquid nitrogen. Tissues were pulverised using a Mikro-
Dismembrator (B-Braun) in the presence of liquid nitrogen.
Patient characteristics are listed in Table I.
Western blot analysis
Western blot analysis was carried out as previously described
(Di Renzo et al., 1991). The powdered whole tissue was
dissolved in boiling sodium dodecyl sulphate (SDS) contain-
ing buffer, in the presence of the reducing agent fi-
mercaptoethanol. Equal amounts of proteins (200 ,ug) were
loaded into each lane. Proteins were separated by poly-
acrylamide gel electrophoresis and transferred to nitrocellu-
lose sheets. Blots were probed with the anti Met/HGF
receptor monoclonal antibodies or anti-HGF/SF antiserum,
and then with HRP-conjugated rabbit anti-mouse immuno-
globulins or Protein-A, revealed by ECL (Enhanced
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Table I Patient characteristics
No ofpatients
Entered
Mean age 65 (range 40-76) years
Sex
Male
Female
Histotype
SCC
AC
LCUC
Stagea
I
II
IIIA
IIIB
IV
Grading
GI
G2
G3
Not determined
42
37
5
23
17
2
23
7
11
0
1
15
15
16
Mean follow-up 12 (range 6- 17) months
a Staging according to Mountain (1986). SCC, squamous cell
carcinoma; AC, adenocarcinoma; LCUC, large-cell undifferentiated
carcinoma.
Chemiluminescence, Amersham, UK). The relative protein
expression was quantified by laser densitometric scanning of
radiographs.
Anti Met/HGF receptor monoclonal antibody (MAb) DQ-
13, used for Western blot analysis, was raised against a
peptide corresponding to 19 C-terminal amino acids (from
Ser'372 to Ser'390) of the c-MET human sequence (EMBL
Data-Bank accession no. X54559). MAb DL-21 used for
Western blot analysis and Mab DO-24 used for immunohis-
tochemistry were directed against the extracellular domain of
the Met protein (Prat et al., 1991). Anti-HGF/SF H04
antiserum was kindly provided by Dr A Galvani (Pharma-
cia-UpJohn, Milan, Italy). It is a HGF/SF fl-chain-specific
antiserum, produced by immunising rabbits with a mixture of
synthetic peptides corresponding to sequences within the #-
chain of the human factor. MAb against HGF (DV-14) was
raised using recombinant HGF/SF secreted by the Spodoptera
frugiperda insect cells (Sf9), which were infected with the
baculovirus vector containing the full size human HGF/SF
cDNA, as immunogen (M Prat et al., in preparation).
Recombinant HGF/SF labelling and immunoprecipitation
Recombinant HGF/SF was produced in Sf9 cells, transfected
with a baculovirus transfer vector containing the full length
HGF/SF cDNA cloned from human liver, as described by
Naldini et al. (1995). The factor (in its uncleaved precursor
form) was purified from tissue culture supernatants by affinity
chromatography on heparin-Sepharose column to near
homogeneity and labelled with Na'251 on iodogen-coated
polypropylene vials at a specific activity of 13 jiCi jig-'. A
fraction of the radiolabelled protein was then incubated at
37°C in the presence of fetal calf serum to induce its
proteolytic cleavage to the a,B-heterodimeric form. Immuno-
precipitation was carried on by incubating both uncleaved
and cleaved forms of radioiodinated HGF/SF with affinity
purified DV-14 MAb in Tris-buffered saline, sodium azide,
0.2% bovine serum albumin, 0.2% TritonX-100, containing
Sepharose protein A, preincubated with rabbit anti-mouse
immunoglobulins.
Immunoprecipitation of HGF/SFfrom tissue samples
For immunoprecipitation, the powdered whole tissue was
dissolved in HEPES buffer (25 mM, pH 7.4) containing 10%
glycerol, 150 mM sodium chloride, 5 mM EDTA, 1 mM
EGTA, 1% TritonX-100 and protease inhibitors (2 mM
phenylmethylsulphonylfluoride, 100 Mg ml-' leupeptin, 5 ,ug
ml-' pepstatin, 100 kIU ml-' aprotinin) at 0°C. Extracts
were clarified and proteins were immunoprecipitated using
anti-HGF MAb. Precipitated proteins were collected and
analysed by Western blot as previously described (Di Renzo
et al., 1995a).
Histological and immunohistochemical staining
Cryostatic sections (4 j/m) were fixed in cold absolute acetone
for 10 min and stained with 0.1% toluidine blue in phosphate
buffered saline (PBS) for histological examination. Other
sections were used for immunoperoxidase (IIP) staining, as
previously described (Natali et al., 1990). To avoid false-
negative results, from heterogeneous distribution of the
epitope, at least three non-consecutive sections of the biopsy
were analysed. IIP was performed using the DO-24 and DV-
14 MAbs as purified antibodies at concentrations ranging
from 10 to 50 jug ml-'. In controls, samples were incubated
with an unrelated MAb of the same isotype. For
photographic documentation, IIP stain was performed using
the ABC Vectastain Elite kit (Mountain View CA USA),
according to the manufacturer's instructions. The enzymatic
activity was developed using 3-amino-9-ethylcarbazole (AEC)
as chromogenic substrate for 8 min. Slides were then rinsed
with PBS and counterstained with Mayer's haematoxylin.
Statistical analysis
Statistical analysis of Met/HGF receptor and HGF/SF
expression in normal and tumour tissue was performed
using the Wilcoxon matched-pairs rank test. Correlation of
tumour stage and histology with increased expression of
either the receptor or the ligand were analysed using the
Pearson R and Spearman correlation tests.
Results
Expression of HGF/SF in human NSCLC
HGF/SF expression was examined in fresh samples of non-
small-cell lung carcinomas with Western blot analysis. Each
carcinoma sample was compared with the unaffected adjacent
tissue. Samples were analysed using an antiserum against the
HGF/SF fl-chain. HGF/SF is secreted as a single chain
precursor (pro-HGF) of the approximate Mr of 92 kDa and
is cleaved to give the mature heterodimer in the extracellular
environment (Naldini et al., 1992). The mature 92 kDa dimer
is composed of a 60 kDa x-subunit disulphide-linked to a
32-36 kDa fl- f32-subunit. fl, and f2 kDa variants differ for
the content of carbohydrates (Weidner et al., 1990); oc- and
,B-,B2-chains of the mature heterodimer are distinct in gels
run in reducing conditions. Specificity of HGF/SF antiserum
was demonstrated by blocking HGF/SF binding with the
peptides used as immunogen (not shown). Additional
experiments showed that HGF/SF antiserum does not
recognise the structurally related HGF-like molecules
plasmin, thrombin and macrophage stimulating protein
(MSP, not shown).
As shown in Figure 1, in most of normal lung tissue
samples the antiserum did not detect any pro-HGF nor the
32-36 kDa fi -fl2-HGF/SF chain. In a few cases (nos 2 and
3, shown in Figure 1), pro-HGF, but not the fl-chain of the
mature HGF/SF, was observed in normal tissues. Twenty-
three out of 42 carcinomas showed a notable increase of
HGF/SF (P<0.0001). In all 23 positive cases, the f-chain of
the processed HGF/SF, but not pro-HGF, was observed
(Figure 1).
Tumours examined were classified according to their
biological and clinical features. Table II shows features of
tumours overexpressing HGF/SF. NSCLC samples over-
expressing HGF/SF belonged to all the histological classes,
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representing 50% of the squamous cell and aden
The majority of tumours examined were
carcinomas (Table I). This did not allow a
statistical analysis of the correlation between o
and disease stage.
2 3 5 6 HGF
n ca n ca n ca n ca
80-
49-
32-
Figure 1 Expression of HGF/SF in human NSCLC samples (ca)
compared with samples of normal lung tissue (n) of the same
patient, detected with Western blot analysis. Numbers on the top
of the lanes indicate different patients. HGF/SF precursor (pro-
HGF) and the fl-chain of the mature heterodimer were labelled
with an antiserum raised against a mixture of synthetic peptides
corresponding to sequences within the fl-chain of the human
factor. Bound antibodies were labelled with HRP-conjugated goat
anti-rabbit immunoglobulins and revealed with ECL (Enhanced
Chemiluminescence). The supernatant of the Sf9 insect cells,
infected with the baculovirus vector containing the full-size
human HGF/SF cDNA, was run for a comparison (HGF).
Native supernatant and that preincubated with fetal calf serum to
get processed HGF were combined. Standards used for Mr
estimation reported on the left were prestained bovine serum
albumin (80000), ovalbumin (49 500) and carbonic anhydrase
(32 500).
ocarcinomas. The 36 kDa form of the HGF/SF fl-chain was the more
stage I-II prominent in NSCLC, as shown in Figure 1 where it is
significative compared with the HGF/SF /3-,/2-chain produced by Sf9
verexpression insect cells infected with the baculovirus vector containing the
full-size human HGF/SF cDNA. As expected, the recombi-
nant HGF/SF /-3 2-chain showed a lower Mr because of the
different post-translational processing.
To further confirm the identity of the 36 kDa protein,
immunoprecipitation experiments with HGF/SF DV-14 MAb
were performed by extracting detergent-soluble proteins from
powdered whole tissues. Specificity of DV-14 MAb is shown
in Figure 2. Additional experiments demonstrated that the
HGF/SF MAb does not recognise the structurally related
Pro-HGF HGF-like molecules plasmin, thrombin and macrophage
stimulating protein (MSP, not shown). Proteins immunopre-
cipitated by MAbs were labelled with anti-HGF/SF
antiserum using Western blot analysis. Control experiments
were performed with unrelated antibodies. As shown in
Figure 3, the 36 kDa protein was precipitated and labelled by
HGF Il-chain anti-HGF/SF antibodies from carcinoma samples and not
from the adjacent normal tissues.
Expression of the Met/HGF receptor in NSCLC
The expression of the Met/HGF receptor was examined in
the same samples with Western blot analysis. The receptor is
a 190 kDa heterodimeric tyrosine kinase composed of two
disulphide-linked chains (Giordano et al., 1989), an extra-
cellular c-chain of 50 kDa and a transmembrane /-chain of
145 kDa. When proteins are separated on SDS-PAGE in the
presence of the reducing agent fi-mercaptoethanol, the
145 kDa /-chain and the 50 kDa oa-chain that constitute the
receptor are distinct. In these conditions the 145 kDa fl-chain
and the p170 precursor were labelled by the DQ-13 MAb
against the C-terminal peptide of the human receptor. A
representative experiment is shown in Figure 4. The Metl
HGF receptor of the NSCLC samples was also labelled by
Table II NSCLCs overexpressing HGF/SF and/or Met/HGF receptor
No. Age Sex Histology Grading TDa Stage"
2
3
S
6
9
10
12
13
16
18
19
20
23
24
25
27
29
30
31
32
34
35
36
40
42
43
59
62
69
74
72
73
54
68
76
67
74
68
65
53
64
70
56
59
72
57
40
62
67
69
70
60
M
M
M
F
M
M
M
M
M
M
M
M
F
M
M
M
F
M
M
M
F
M
M
M
M
M
SCC
AC
AC
AC
AC
SCC
LCUC
SCC
SCC
SCC
SCC
AC
AC
SCC
SCC
SCC
SCC
AC
SCC
SCC
AC
SCC
SCC
SCC
SCC
AC
G3
G3
ND
G3
ND
G3
ND
G3
Gl
ND
G2
ND
ND
G3
G2
G2
G3
ND
G3
G3
ND
G3
G2
G2
G2
ND
6.5
3.0
1.2
3.0
5.0
6.0
1.4
4.0
1.8
6.0
5.5
4.5
4.0
8.5
3.0
5.0
5.0
5.0
6.0
5.0
8.5
4.0
3.2
4.5
6.0
7.0
IIA
IIA
I
I
IIA
II
I
I
IIA
I
III
II
II
II
IV
I
IIIA
MetR'
+
+
++
++
+
++
++
+
+
+
+
++
+
+
+
++
+
+
HGP
±+
+ +
+ +
+ +
+ +
+±±
+ +
+±+
+ +
+ +
±1+
+ +
+±+
'TD, tumour diameter (cm). bStaging according to Mountain (1986). CExpression of Met/HGF receptor
(MetR) was detected with Western blot analysis; the score relative to normal lung tissue ofthe same patient was
as follows: (-), negative samples; (+), detectable expression as in the normal counterpart; (+ +), 2 -5-fold and
(+ + +), more than 10-fold increase. d Expression of HGF was detected with Western blot analysis; the score
was: (-), negative samples; (+), detectable expression; (+ +), 2-5-fold and (+ + +), more than 10-fold
increase relative to the lowest level ofexpression detected in carcinomas. e In this case high level ofpro-HGF was
found in the normal tissues (see Figure 1). ND, not determined. SCC, squamous cell carcinoma; AC,
adenocarcinoma; LCUC, large cell undifferentiated carcinoma.HGF/SF in NSCLC
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Figure 2 The specificity of anti-HGF/SF DV-14 MAbs is
assayed on 1251-labelled HGF/SF, purified from supernatants of
Sf9 cells infected with the baculovirus vector containing the full-
size human HGF/SF cDNA. When precipitated, HGF was
separated in SDS-PAGE analysis in non-reducing conditions
(NR); it appears as a single band of about 70kDa, corresponding
to both the mature heterodimeric a,B complex and the uncleaved
HGF/SF precursor (pro-HGF). This band is resolved under
reducing conditions (R) in three bands corresponding to pro-
HGF (Mr92), the a- and the /3-chains of 60kDa and 32-36kDa
respectively. The two forms of HGF/SF are present, i.e. the
uncleaved pro-HGF/SF produced by transfected Sf9 cells and the
mature biologically active heterodimer, as precipitation has been
performed purposely in the presence of fetal calf serum, which is
known to contain a protease able to cleave pro-HGF/SF
(Shimomura et al., 1995). Standards used for Mr estimation
were prestained myosin (205000), ,B-galactosidase (116500),
bovine serum albumin (80000), ovalbumin (49 500) and carbonic
anhydrase (32 500).
29 30
n Ca n ca HGFcon
49-
32-
27-
Figure 3 Western blot analysis of HGF/SF immunoprecipitated
by anti-HGF/SF DV-14 MAb from human NSCLC samples (ca)
compared with samples of normal lung tissue (n) of the same
patient. Numbers on the top of the lanes indicate different
patients. Western blot analysis with HGF antiserum was carried
out as described in the legend to Figure 1. As a control, HGF/SF
was also immunoprecipitated from supernatant of the Sf9 insect
cells, infected with the baculovirus vector containing the full size
human HGF/SF cDNA (HGF), and from control supernatant of
non-infected Sf9 cells (con). Standards used for Mr estimation
were prestained ovalbumin (49 500), carbonic anhydrase (32 500)
and soybean trypsin inhibitor (27000).
DL-21 MAb directed against the extracellular domain of the
receptor (not shown). The receptor was detectable in most
normal lung and carcinoma samples. No gross structural
alterations of the protein were ever detected in NSCLC. In 11
out of 42 carcinomas the expression was increased 2 to 10-
fold relative to normal tissues (P=0.0113; Table II).
Increased levels of receptor expression were found in
approximately 25% of both squamous cell (6/23) and
adenocarcinomas (4/17) and in one of the two large-cell
undifferentiated carcinomas. The panel shown in Figure 4
includes squamous cell carcinomas (case no. 2) and
adenocarcinomas (cases no. 6 and 9). Statistical analysis of
the correlation between overexpression and disease stage and
overexpression and tumour histology was performed.
HGF P-chain
205
116-
80-
p170MET
+-p145MET
Figure 4 Expression of the Met/HGF receptor in NSCLC
samples (ca) compared with samples of normal lung tissue (n)
of the same patient, detected with Western blot analysis. Numbers
on the top of the lanes indicate different patients. The p145 ,B-
chain and the p170 precursor of the Met/HGF receptor were
labelled by DQ-13 MAbs raised against a synthetic peptide
corresponding to the C-terminal tail of the human receptor.
Bound antibodies were labelled with HRP-conjugated rabbit anti-
mouse immunoglobulins and revealed with ECL (Enhanced
Chemiluminescence). Standards used for Mr estimation were
prestained myosin (205000), ,B-galactosidase (116500) and bovine
serum albumin (80000).
Adenocarcinomas showed a trend in overexpression of the
Met/HGF receptor (according to Pearson R test).
Immunohistochemical localisation
To ascertain the localisation of HGF/SF and Met/HGF
receptors in NSCLC, tissue samples were stained by
immunohistochemistry using the DV-14 and DO-24 Mab
respectively (see the Methods section). Staining of normal
lung tissues with MAb to the Met/HGF receptor (not shown)
revealed no immunoreactivity with alveolar walls, lymphoid
tissues, cartilage, bronchial glands and vascular walls. A
weak staining was observed in the basal aspect of the
bronchial epithelium. HGF/SF expression was undetectable
in normal tissues by immunohistochemistry with anti-HGF
MAb (not shown).
As shown in Figure 5, when comparing carcinoma areas to
adjacent normal tissues, a much stronger reactivity for both
the ligand and the receptor was detected in carcinomas.
Although a cell-specific localisation was not feasible on the
basis of the pictures obtained, the Met/HGF receptors
appeared homogeneously distributed in the tumour mass
and localised at the cell surface; whereas the ligand was
detected in the cytoplasm of single or grouped cells, scattered
in the tumour sample.
Discussion
Several reports describe an increased expression of growth
factors and growth factor receptors in human tumours. In
many instances, paracrine and autocrine loops have been
implicated in growth control of cancer cells. However, the
contribution of each growth factor and receptor to the
pathogenesis of human cancer is debatable. It is reasonable to
speculate that the interplay between different factors and
receptors, rather than a single element, play a major role in
determining cell proliferation, cell death or both. Here we
report that HGF/SF is overexpressed in NSCLC. Data
presented here are interesting because of: (1) the HGF/SF
property to stimulate not only mitogenesis, but also cell
motility and invasiveness; (2) the fact that both the factor
and the receptor, encoded by the c-MET oncogene, are
present in tumour samples; (3) the fact that both the receptor
and the ligand are overexpressed in a significant percentage
NR. RHGF/SF in NSCLC
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Figure 5 Indirect ABC immunoperoxidase detection of the Met/
HGF receptor (a) and HGF/SF (b and c) on cryostatic sections of
NSCLC. a and b are sections of the same clinical case (Grade 2
adenocarcinoma). The receptor, detected with the DO-24 anti-
Met MAb, is homogeneously expressed in adenocarcinoma cells
(a) whereas HGF expression, detected with the DV-14 anti-HGF
MAb, is heterogeneously distributed in the cytoplasm of scattered
cells in both adenocarcinoma (b) and in a Grade 3 squamous cell
carcinoma (c). (a, x 200; b and c, x 120 original magnification).
of NSCLCs compared with expression in normal tissue of the
same patients; (4) the marked level of HGF/SF over-
expression; and, in particular, (5) the presence of HGF/SF
in its biologically active form in NSCLC.
HGF/SF is a cytokine with unique properties (exerting
multiple functions), such as mitogenic and motogenic effects
on a variety of normal and transformed cells, and angiogenic
(Bussolino et al., 1992; Grant et al., 1993) and morphogenic
activity (Montesano et al., 1991). These diverse activities are
mediated via a single receptor encoded by the c-MET
protooncogene (Naldini et al., 1991; Weidner et al., 1993),
overexpressed and/or activated in transformed cells (Cooper
et al., 1984; Di Renzo et al., 1991; Giordano et al., 1989;
Park et al., 1986). Hence, it is believed that HGF/SF and its
receptor play a role in cell growth not only during
development and organ regeneration, but also in tumorigen-
esis.
It is known that the Met/HGF receptor is expressed in the
normal lung, in primary NSCLC and in NSCLC cell lines (Di
Renzo et al., 1991; Prat et al., 1991; Tsao et al., 1993; Liu
and Tsao, 1993). On the contrary, HGF/SF mRNA was
detected only at a very low level by reverse transcriptase-
polymerase chain reaction in the normal lung. This level was
increased only after regeneration that follows chemical lung
injury in rats (Yanagita et al., 1993). In vitro, HGF/SF
stimulates mitogenesis and/or motogenesis of bronchial
epithelial cells (Tsao et al., 1993) and alveolar type II cells
(Mason et al., 1994). Here, we show that both HGF/SF and
the MetlHGF receptor are co-expressed (and overexpressed
at a significant percentage) in clinical samples of NSCLC,
suggesting that ligand and receptor might interact via either a
paracrine or autocrine mechanism. Both these mechanisms
were hypothesised on the basis of in vitro experiments in
cultured cells (Naldini et al., 1991; Liu and Tsao, 1993; Tsao
et al., 1993). Whatever the action mechanism might be,
overexpression supports the idea that a local activation of the
biological activities mediated by the Met/HGF receptor
occurs in vivo.
HGF/SF, in particular, is expressed at a considerably high
level in NSCLC; bearing in mind that in normal lung, in
other organs and also in cell lines, the protein is often barely
detectable and the corresponding mRNA is present at very
low levels. HGF/SF expression is controlled primarily at
transcription level and is cell type-specific (Liu et al., 1994;
Planschke-Schutter et al., 1995). It is regulated during
development (DeFrances et al., 1992; Sonnenberg et al.,
1993), and by hormones and cytokines (Matsumoto et al.,
1992a, b; Moghul et al., 1994; Tamura et al., 1993) in a
variety of tissues under physiological and pathological
conditions. Among the regulatory molecules, injurin, which
is produced by injured organs, is known to influence HGF/
SF gene expression (Matsumoto et al., 1992a). One or more
of the factors produced either by cancer cells themselves or
by the accompanying inflammatory cells or by the
surrounding injured tissues might be responsible for the
increased expression of HGF/SF into, or in the proximity of,
NSCLC. Immunohistochemistry does not allow single cell
localisation of HGF/SF. However, the pattern of antibody
staining in serial section of the same tumours suggests that
stromal cells or inflammatory cells rather than the epithelial
tumour cells are responsible for HGF production.
HGF/SF was overexpressed and invariably found in the
cleaved biologically active form in 50% of NSCLCs. By
contrast, in the corresponding normal tissues, HGF/SF was
occasionally detected and was exclusively in the inactive
single chain pro-HGF form. It has been shown that native
HGF/SF is secreted by cells as pro-HGF. Activation takes
place by proteolytic cleavage of pro-HGF at the Arg494-
Val495 bond. Processing to the mature heterodimer is
necessary for HGF/SF to become competent in activating
the Met/HGF receptor and to induce biological responses in
target cells. Three converting enzymes have been described so
far in serum and tissues (Naldini et al., 1992; Mars et al.,
1993; Miyazawa et al., 1993; Shimomura et al., 1995); these
are serum proteases, such as blood coagulation factor XIIa
and its homologous protein named HGF-activator, and the
urokinase-type plasminogen activator (uPA). Of these three,
serum proteases might bring about quantitative activation of
pro-HGF when the blood coagulation cascade is triggered,
for example after tissue injury (Miyazawa et al., 1994).
However, new results have shown that HGF/SF produced
and secreted after partial hepatectomy or unilateral
nephrectomy remains as an inactive single chain (Tang et
al., 1995). On the other hand, uPA which is increased at the
surface of cancer cells, may trigger a more specific local
activation of pro-HGF on membrane of target cells and in
tissue microenvironment (Naldini et al., 1995). In tissueHGF/SF in NSCLC
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microenvironment, macrophages, which are the most efficient
activators of pro-HGF (Naldini et al., 1995), may play an
additional role. A correlation between uPA activity and
tumour cell invasion and metastasis has been well
documented. It is worth noting that a correlation between
the expression level of both uPA and uPA inhibitors and the
onset and progression of human NSCLC has been reported
(Liu et al., 1995; Nagayama et al., 1994). The enhanced
expression of uPA or the reduction of uPA inhibitors might
result in the activation of pro-HGF and in the stimulation of
a circuit to induce growth and invasion through the Metl
HGF receptor.
In vitro, carcinogenesis may be achieved via a 'single hit'
event. It is known that the transformed phenotype is attained
after single high-level overexpression of the viral ras or after
an autocrine loop is established. Similarly, in vitro over-
expression of many growth factor receptors results in ligand-
dependent transformation. In these cases, a quantitative effect
may be envisaged. In vivo, carcinogenesis is usually a complex
multi-step process, involving deletion of tumour-suppressor
genes and activation of dominant oncogenes. In NSCLC, the
accumulation of ras mutation, p53 mutation and over-
expression of growth factors and growth factor receptors
have been reported and were associated with the malignant
phenotype of tumour cells and/or to patient survival
(Ankrapp and Bevan, 1993; Carbone et al., 1994; Liu and
Tsao, 1993; Rosell et al., 1993; Yu et al., 1994). Here, we
report that the expression of HGF/SF is markedly increased
in NSCLC and, more notably, HGF/SF is activated in cancer
samples. Several reports implicated HGF/SF in tumour
progression and metastasis. Met/HGF receptor activation
induces cell motility (Stoker et al., 1987), invasion of collagen
matrices (Weidner et al., 1993), activation and secretion of
proteases (Rong et al., 1994) and angiogenesis (Bussolino et
al., 1992; Grant et al., 1993). The expression of a functional
c-MET-encoded receptor is sufficient to transfer an invasive
phenotype to transfected cells in the presence of HGF
(Giordano et al., 1993). The creation of an HGF autocrine
loop either in fibroblasts or in epithelial cells induces invasive
properties in vitro and metastatic ability in vivo (Rong et al.,
1994; Bellusci et al., 1994). Liver metastases of human
colorectal cancer show overexpression and amplification of
the c-MET oncogene (Di Renzo et al., 1995b). In conclusion,
the overall data suggest that HGF/SF overexpression and
activation may be the driving factor for NSCLC cell invasive
phenotype acquisition.
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